Gelatin stabilized iron oxide nanoparticles as a three dimensional template for the hydroxyapatite crystal nucleation and growth

Inspired by the structural similarity of gelatin (and collagen) linked to a mineral phase based on Ca-phosphates compounds with natural bone and increasing application of magnetic iron oxides in hyperthermia, gelatin coated iron oxide (GIO) was synthesized and hydroxyapatite (HAp) crystal nucleation and growth in the nanoparticles was explored. A series of GIO/HAp nanocomposites with various amount of GIO were synthesized by co-precipitation technique using calcium hydroxide and phosphoric acid as precursor. Various physico-chemical analysis showed that the HAp crystal nucleation and growth occurred at acidic group of gelatin, while magnetic iron oxide nanoparticles (\u3c 8nm) were bound to the amide groups of the gelatin chain. Moreover, the growth of HAp nanocrystals in aq. GIO solution was highly influenced by the GIO contents in the solution. The mineralized composite with magnetic properties could have great scope in biomedical field as a thermoseed to kill the cancerous cell in bone side by side for the bone reinforcement

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN